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Cells
Juan Xiao1,2,3*, Rongbing Yang2*, Lin Yang1, Xiaohang Fan1, Wenwei Liu1 & Wenbin Deng1,3
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Experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS), is characterized by
CNS demyelination mediated by autoreactive T cells. Kirenol, a biologically active substance isolated from
Herba Siegesbeckiae, has potent anti-inflammatory activities. Here we investigated effects of kirenol on
EAE. Kirenol treatment markedly delayed onset of disease and reduced clinical scores in EAEmice. Kirenol
treatment reduced expression of IFN-c and IL-17A in the serum and proportion of Th1 and Th17 cells in
draining lymph nodes. Priming of lymphocytes was reduced and apoptosis ofMOG-activated CD41 T cells
was increased in kirenol treated EAE mice. Kirenol treatment of healthy animals did not affect the
lymphocytes in these non-immunized mice. Further in vitro studies showed that kirenol inhibited viability
of MOG-specific lymphocytes and induced apoptosis of MOG-specific CD41 T cells in a dose- and
time-dependent manner. Kirenol treatment upregulated Bax,downregulated Bcl-2,and increased activation
of caspase-3 and release of cytochrome c, indicating that a mitochondrial pathway was involved in kirenol
induced apoptosis. Moreover, pretreatment with either a pan-caspase inhibitor z-VAD-fmk or a more
specific caspase 3 inhibitor Ac-DEVD-CHO in lymphocytes reduced kirenol induced apoptosis. Our
findings implicate kirenol as a useful agent for the treatment of MS.
E
xperimental autoimmune encephalomyelitis (EAE) is a commonly used animal model of multiple sclerosis
(MS), the most common chronic neuroinflammation and demyelinating disease of the central nervous
system (CNS) in humans1–3. During the course of EAE, anti-myelin autoreactive lymphocytes invade the
CNS, leading to demyelination lesions and inflammation4. The ongoing paralysis and other neurological symp-
toms in EAE are difficult tomanage and treat effectively. Both Th1 and Th17 cells are considered to be pathogenic
T cell populations for the autoimmune inflammatory demyelination of CNS in EAE5–9, and the levels of Th1/Th1
cells control the development of EAE. Therefore, it is important to understand the mechanisms controlling the
generation of Th1/Th17 cells in EAE. A number of mechanisms have been described to contribute to the
maintenance of immune homeostasis in autoimmune CNS diseases. One such mechanism is activation induced
cell death (AICD)10–12, a form of apoptosis or programmed cell death, and defect in this form of apoptosis may
lead to development of autoimmune diseases including EAE. In T cell mediated CNS demyelination in EAE,
AICD selectively eliminates the mature effector myelin-reactive T cells. Therefore, AICD contributes to down-
regulation of inflammatory T cell activity and inhibits inflammatory responses that trigger the clinical symptoms
of EAE.
Kirenol is a diterpenoid natural product compound isolated from Herba Siegesbeckia, where a gram of dried
Herba Siegesbeckia contained 0.482–1.302 mg of kirenol13,14. The active fraction of Herba Siegesbeckia extracts
reduced the inflammatory pathology in collagen induced arthritis and led to increased IL-2 but decreased IL-1
levels in the serum15. It has also been reported that kirenol possesses anti-inflammatory, anti-arthritic and
immunoregulatory activities13,16,17. Kirenol upregulated nuclear Annexin-1, inhibited NF-kB activity and reduced
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expression of IL-1b to inhibit inflammatory response in arthritis18.
Our previous study showed amelioration of autoimmune arthritis by
kirenol, owing to modifying T cell balance and reduced secretion of
pro-inflammatory cytokines17. Despite the well-documented anti-
inflammatory properties of kirenol, whether kirenol ameliorates
autoimmunity has not been investigated.
In the present study, we investigated the effects of kirenol and the
mechanisms of action on the development of EAE. Our results
showed that kirenol treatment significantly inhibited EAE. The
reduced pathology of kirenol treated mice was associated with a
decreased proportion of Th1/Th17 cells together with lower levels
of IFN-c and IL-17A in the serum and increased apoptosis of auto-
reactive lymphocytes in the draining lymph nodes (DLNs). Further
in vitro studies showed that kirenol induced apoptosis of myelin
reactive T cells and a mitochondrial pathway might be involved in
the apoptosis induced by kirenol.
Methods
Chemicals and reagents. Kirenol (purity of.99%) was obtained from the State Key
Laboratory of Natural and Biomimetic Drugs at Peking University (Beijing, China).
Kirenol was resuspended in distilled water and the chemical structure of kirenol
shown in Fig. 1A. Antibodies detected for the following targets were purchased as
indicated: Caspase-3 fromCell Signaling Technology; Bax and Bcl-2 from Santa Cruz
Biotechnology; and b-actin from Sigma. Phorbol 12-myristate 13-acetate (PMA) and
ionomycin were purchased from Sigma-Aldrich. Mouse Th1/Th17 phenotyping kit
and Perm/Fix solution were purchased from BD Biosciences (USA). IFN-c and IL-
17A ELISA kit were purchased from eBioscience (USA). FITC-anti-CD4 and PE-
anti-AV were purchased from Sungene Biotech (Tianjin, China). The MOG35–55
peptide (MEVGWYRSPFSRVVHLYRNGK) was synthesized by Chinese Peptide
Company (Hangzhou, China). DyLight 800/DyLight 680-conjugated secondary
antibodies against mouse or rabbit IgG were purchased from Rockland
Immunochemicals (USA).
Induction, clinical evaluation and treatment protocols of EAE.C57BL/6mice were
bred at the Experimental Animal Center, Peking University Health Sciences Center.
All experimental procedures and protocols were approved by the Peking University
Animal Ethics Committee and were performed in accordance with the institutional
guidelines and regulations. EAE was induced by MOG35–55 in female mice used
between 8 and 10 weeks of age. Briefly, each mouse was immunized subcutaneously
with 300 mg of MOG35–55 emulsified with an equal volume of complete Freund’s
adjuvant (CFA, total 300 mg of Mycobacterium tuberculosis, strain H37RA, Difco,
USA) and then injected to the caudal vein with 200 ng of pertussis toxin (PTX)
(dissolved in 200 ml PBS, List Biological Laboratories, USA) at the time of
immunization and 2 days later. Mice were examined for clinical scoring daily by the
same investigator for 25 days after immunization in a blinded manner. Neurological
assessments were reported using a five-point standardized rating scale to evaluate
motor deficit: 0, no deficit; 1, tail paralysis; 2, incomplete hind limb paralysis; 3,
complete hind limb paralysis; 4, complete hind limb paralysis and partial forelimb
paralysis; 5, moribund state or death.
After the immunization of MOG35–55 on day 0, healthy (non-immunized) or EAE
mice were administered daily with oral gavage of 2 mg/kg kirenol from day 0 to day
25. The no-drug control groups were administered daily with equal volumes of
distilled water.
Histological examination. Histological analysis was performed on lumbar spinal
cords obtained from EAE or non-immunized mice at day 25 after immunization.
Figure 1 | EAE disease severity is reduced in kirenol treatedmice. (A) The chemical structure of kirenol. (B) EAEwas induced and treatedwith kirenol or
distilled water (n 5 18 per group). Mean clinical disease scores are mean 6SD. (C) Histological sections of the lumbar spinal cord from EAE or control
(non-immunized) mice at day 16 after immunization. Sections are stained with H&E and representative images are shown. The scale bar represents
100 mm.
www.nature.com/scientificreports
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Following anesthesia with intraperitoneal administration of pentobarbital, each
mouse was perfused with 4% paraformaldehyde in 0.1 M phosphate buffer. Each
spinal cord was carefully removed and immersed in the same fixative. The lumbar
segments of each spinal cord were embedded in paraffin. Five-mm-thick sections
were prepared and stained with hematoxylin-eosin (H&E).
Flow cytometry analysis. The DLNs from the EAE or non-immunized mice were
harvested at day 25, and a single cell suspension was prepared. To quantify the
number of Th1/Th17 cells, cells were stimulated with PMA and ionomycin in the
presence of brefeldin A for 5 h. Subsequently, cells were surface-stained with anti
CD4-FITC, permeabilized with Perm/Fix solution and stained with anti-IFN-c-PE
and anti-IL-17A-PE. Isotype-matched IgGwas used as a negative control. The stained
cells were analyzed by FACS Caliber using Cell Quest software (BD Biosciences,
USA). For detection of apoptosis, lymphocytes from DLNs with EAE or non-
immunized mice were harvested and stimulated with or without of 20 mg/ml of
MOG35–55 peptide together with different concentration of kirenol for different time.
Then cells were collected and stained with anti-CD4-PE/AnnexinV-FITC, and
proportion of CD41 Annexin V1 cells were analyzed by flow cytometry.
Lymphocyte proliferation assay and detection of cytokines in supernatant and
serum. To investigate the antigen-specific lymphocytes response to MOG35–55,
lymphocytes from DLNs at day 25 were seeded at 5 3 105 cells/well in 96-well plates
with RPMI 1640 containing 10% fetal calf serum (FCS) and stimulated with or
without 20 mg/ml of MOG35–55 peptide. After 48 h, cells were pulsed with 1 mCi/well
[3H]-thymidine (MP Biomedicals, USA) and incubated for an additional 8 h. The
results are expressed as mean [3H] thymidine incorporation (cpm) 6 standard
deviation (SD).
Cell sorting andWestern blot analysis. Lymphocytes form DLNs in EAEmice were
stained with anti-CD4 antibodies and sorted on a FACS instrument (BD Biosciences,
USA) by gating on the CD41 population. For western blot analysis experiment, the
sorted CD41 T cells were lysed in lysis buffer (300 mM NaCl, 50 mM Tris pH 8.0,
0.4% NP-40, 10 mM MgCl2, and 2.5 mM CaCl2) supplemented with protease
inhibitors (Complete mini EDTA-free; Roche Diagnostics, Mannheim, Germany).
After centrifugation, the supernatant was measured using the BCA protein assay
reagent (Pierce, Rockford, IL). Then, 1 mg of total cell extracts protein was loaded
onto 12.5% SDS-PAGE, transferred to nitrocellulose membrane (Amersham
Pharmacia Biotech, Little Chalfont, UK), blocked by incubation with 5% non-fat milk
in TBS-T buffer (10 mM Tris–HCl, pH 7.4, 150 mM NaCl and 0.1% Tween-20) for
1 h, and blotted against the different proteins using specific antibodies: anti-caspase-
3, anti-Bax, anti-Bcl-2, anti-b-Actin and anti-cytochrome c. After washings with TBS,
the protein bands were visualized using DyLight 800/DyLight 680-conjugated
secondary antibodies, and the infrared fluorescence image was obtained using an
Odyssey infrared imaging system (LI-COR Biosciences, USA).
Caspase 3 activity assay. Briefly, lymphocytes from DLNs of EAE mice were
incubated in a 48-well plate with 2 3 106 cells per well and treated with the indicated
concentration of drugs. Cells were then collected and sorted for CD41 T cells.
Caspase3 activity was measured using a caspase 3 activity assay kit (Beytime, China)
according to the manufacturer’s instructions. The absorbance was measured at
405 nm using a microplate reader. The experiments were carried out in triplicate.
Results
Kirenol suppresses the pathogenesis of EAE. After immunization
of MOG35–55 on day 0, the mice were treated with a daily oral gavage
of kirenol or saline for 25 d, and regularly graded for signs of EAE.
Both the day of clinical onset and the day of peak clinical disease were
delayed in kirenol treatedmice compared to saline treated EAEmice.
The peak clinical score of kirenol treated EAE mice was significantly
lower compared with that of saline treated mice (Fig. 1A, 1B). His-
tological examinations of the lumbar spinal cord tissue collected on
day 25 post immunization revealed that massive inflammatory
infiltration was evident in the spinal cord of EAE mice. However,
minimal infiltration of inflammatory lymphocytes was found in
kirenol treated EAE mice (Fig. 1C). Kirenol did not affect lympho-
cyte infiltration in non-immunized mice (Fig. 1C). Together, these
results indicated that kirenol treatment significantly reduced the
demyelination of CNS during EAE.
Kirenol decreases the differentiation of IFN-c and IL-17A pro-
ducing CD41 T cells in vivo. To investigate the immunological
mechanisms associated with the reduced severity of EAE in kirenol
treated mice. Serum samples were collected at 25 days after immu-
nization and cytokine levels were measured by ELISA. Kirenol
treated EAE mice produced significantly low level of serum IFN-c
and IL-17A compared with saline treated mice (Fig. 2A, 2B). The
results indicated that kirenol downregulated the inflammatory Th1/
Th17 response in vivo. Next, we examined the cellular phenotypes of
EAE mice treated with kirenol and saline. Single cell suspensions
were prepared from the DLNs of EAE mice at day 25 after immu-
nization as described above, and stained for cell surface and intrace-
llular markers by flow cytometry. Consistent with the cytokines
profile observed above, there was a significant reduction in the
frequency of IFN-c1 and IL-17A1 cells in the DLNs from EAE
mice treated with kirenol (Fig. 2C, 2D, 2E, 2F) compared to mice
treated with saline. Kirenol did not affect concentration of cytokines
in healthy (non-immunized) animals. Together, these data indicated
in vivo downregulation of inflammatory Th1/Th17 cells in the EAE
mice treated with kirenol.
Kirenol reduces effector and effector memory CD41T cells in the
DLNs in vivo. In secondary lymphoid organs such as DLNs, priming
of CD41 T cells plays an important role in the development of auto-
reactive T cell responses and subsequent inflammatory pathology in
EAE. To determine if the diminished clinical presentation of
autoimmunity in kirenol treated mice was related to defects in T
cells priming, lymphocytes obtained from DLNs were gated on
CD41 T cells, and CD62L, CCR7, CXCR3, CCR6 and CD44high/
CD62Llow expression on CD41 T cells were analyzed by flow
cytometry. As shown in Fig. 3A and Fig. 3B, a higher proportion of
CD41 T cells in DLNs of kirenol treated mice expressed markers of
naı¨ve T cells (CD62L andCCR7). Furthermore, a lower proportion of
CD41 T cells were positive for markers of effector T cells such as the
chemokine receptors CXCR3 and CCR6 (Fig. 3C, 3D), and expressed
an effector/memory phenotype (CD44high/CD62Llow) (Fig. 3E).
Kirenol did not affect CD41 T cells from non-MOG immunized
mice. These results indicated less efficient T cell (MOG-specific)
activation in kirenol treated mice.
Kirenol induces apoptosis of MOG-specific T cells in vivo and in
vitro. Next, the response of autoreactive lymphocytes to MOG35–55
in DLNs from EAEmice treated with saline or kirenol was measured
by [3H]-thymidine incorporation assay. Significantly lower [3H]-
thymidine incorporation was seen in cells from mice treated with
kirenol (Fig. 4A), indicating impaired immune priming of effector T
cells in kirenol treated mice. The defect in T cell priming could be a
result of impaired T cell proliferation or survival, or a combination of
both. We then assessed the apoptosis of CD41 T cells from DLNs of
EAEmice treated with kirenol.We observed that a higher proportion
of apoptotic cells were present in DLNs of kirenol treated mice
compared to saline treated mice (Fig. 4B), indicating that kirenol
promoted apoptosis of CD41 T cells.
We further investigated the effects of kirenol in antigen-specific
lymphocytes proliferation in vitro. Lymphocytes of DLNs from EAE
mice were incubated with MOG35–55 together with increasing con-
centrations of kirenol. As shown in Fig. 5A, lymphocytes prolifera-
tion was reduced in a time-dependent manner when cultured in the
presence of kirenol, indicating that kirenol inhibited priming of
effector cells. To assess if the observed reduction in cell viability
was due to apoptosis, lymphocytes were incubated with MOG35–55
together with increasing concentrations of kirenol, and the percent-
age of CD41 Annexin V1 was analyzed by flow cytometry. As
shown in Fig. 5B, the proportion of CD41 T cells cultured with
kirenol underwent apoptosis in a concentration-dependent manner,
indicating that kirenol promoted apoptosis of CD41 T cells.
Kirenol induces MOG-specific T cells apoptosis via a mitochon-
drial pathway. To further investigate the mechanisms of the
induction of apoptosis in MOG-specific T cells induced by kirenol,
lymphocytes fromDLNs in EAEmice were stimulated withMOG35–
55 together with the indicated concentrations of kirenol for 36 h and
then gated on CD41 T cells and measured for the expression of
apoptosis-related proteins by western blot analysis. The results
www.nature.com/scientificreports
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showed that Bax expression was dose-dependently increased, whereas
Bcl-2 expression was dose-dependently decreased. Furthermore, a
dose-dependent elevation of cleaved caspase 3 was seen in kirenol
treated CD41 T cells (Fig. 6A). Next, lymphocytes were stimulated
with MOG35–55 together with either the pan-caspase inhibitor z-
VAD-fmk (10 mM) or a more specific caspase 3 inhibitor Ac-
DEVD-CHO (10 mM) for 4 h and with kirenol (20 mM) for
another 36 h and then gated on CD41 T cells. We found that the
relative activities of caspase 3 were increased in CD41 T cells treated
with kirenol only (Fig. 6B). Furthermore, CD41 T cells pretreated
with z-VAD-fmk or Ac-DEVD-CHO strongly reduced kirenol-
induced apoptosis (Fig. 6C, D). The expression of cytochrome c
released from mitochondria into the cytoplasm during apoptosis
was also examined. As shown in Fig. 6E, kirenol increased the
expression of cytochrome c in a dose dependent manner. These
findings indicated that a mitochondria-dependent pathway was
involved in apoptosis induced by kirenol.
Discussion
This study revealed novel anti-inflammatory therapeutic effects of
kirenol in a CNS autoimmune disease. First, we showed that it
delayed the onset and decreased the clinical scores of EAE in mice.
Second, we demonstrated that the amelioration in EAE pathology
was due to decrease in the proportion of Th1/Th17 cells, but also
attributed to T cell activation and higher levels of AICD in T cells.
Third, we found that amitochondrial pathway was involved in apop-
tosis induced by kirenol.
EAE is mediated by the auto-myelin reactive T lymphocytes that
enter into the CNS and secrete pro-inflammatory cytokines, lead-
ing to the formation of inflammatory and demyelinating lesions19.
Th1 cells were considered to be the critical T-helper cells for the
autoimmune inflammation in the brain, and then the discovery of
Th17 cells critically improved our understanding of the cellular
basis of EAE pathogenesis8,20. Increasing evidence has shown that
both Th1 and Th17 cells drive the pathogenesis of EAE, but neither
cell type can induce the same extent of EAE without contribution
from the other21–23. Regulatory T (Treg) cells are known as a subset
of CD41 T cells that are essential for controlling autoimmune
inflammation by suppressing autoreactive T cells, and are able to
inhibit the pathogenesis of EAE24,25. In the present study, the
reduced clinical signs and pathologies in EAE mice treated with
kirenol were unlikely due to the enhanced Treg response, as there
was no apparent increase in the proportion of Treg cells during the
EAE course,. We showed that the generation of Th1/Th17 cells and
secretion of IFN-c and IL-17A were reduced in kirenol treated
mice.
Figure 2 | Th1/Th17 cells are reduced in kirenol treated EAE mice. Serum from EAE or control (non-immunized) mice at day 25 was obtained and the
concentration of INF-c (A) and IL-17A (B) was measured by ELISA. (C) Representative image of CD41IFN-c1 flow cytometry. (D) Quantification of
the number of CD41IFN-c1 Th1 cells. (E) Representative image of CD41IL-17A1 cells by flow cytometry. (F) Quantification of the number of
CD41IL-17A1 Th17 cells.
www.nature.com/scientificreports
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Figure 3 | T cell priming is reduced in kirenol treated EAE mice. Lymphocytes were obtained from DLNs of EAE or control (non-immunized) mice at
day 25 after immunization. Priming of T cells was reduced in EAE mice treated with kirenol as demonstrated by higher proportion of CD62L1 (A) and
CCR71 (B) T cells that gated on CD41 T cells and lower proportion of CXCR31 (C) or CCR61 (D) T cells that gated on CD41 T cells. (F) The
proportion of memory T cells (CD41CD44highCD62Llow) in DLNs was lower in kirenol treated EAE mice.
Figure 4 | T cell apoptosis is reduced in EAE mice treated with kirenol. Lymphocytes of DLNs were obtained from EAE or control (non-immunized)
mice at day 25. Lymphocytes were stimulated with or without MOG35–55 for 48 h, and then cell proliferation was measured by [
3H]-thymidine
incorporation assay. (B) Representative images of CD41AV1 flow cytometry in DLNs are shown. (C) Quantification of the number of CD41AV1 cells
in DLNs.
www.nature.com/scientificreports
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During autoimmune response, the magnitude of autoreactive T
cell response against a specific antigen is determined by the balance
between the increasing number of antigen-specific T cells and loss of
antigen-specific T cells by AICD. A previous report showed that
administration of apoptosis inhibitors resulted in impaired recovery
and earlier relapse in EAE by suppressing apoptosis of inflammatory
cells26. However, other studies reported that induction of autoreac-
tive T cell apoptosis reduced disease severity in EAE27,28. Our study
showed that kirenol inhibited the survival of mature antigen-specific
T cells, as a higher proportion of naı¨ve T cells but a lower proportion
of effector/memory T cells were observed in the DLNs of kirenol
treated mice. Further in vivo and in vitro studies demonstrated that
kirenol inhibited the survival of antigen-specific T cells by inducing
apoptosis.
In lymphocytes, apoptosis can be triggered by the extrinsic path-
way activated by the death receptor and the intrinsic pathway acti-
vated by Blc-2 family members and caspase cascades within the
mitochondria29. In the intrinsic pathway of apoptosis, activation of
Bax leads to mitochondrial dysfunction and cell death. The Bax
protein can form heterodimers with the apoptosis inhibitor Bcl-2,
and the relative levels of these two molecules determine the death of
the cells30. In the present study, kirenol treatment increased the
expression of Bax but decreased the expression of Bcl-2 in lympho-
cytes of DLNs in a dose-dependent manner. An increased ratio of
pro- and anti-apoptotic protein expression, such as Bax/Bcl-2 ratio,
may lead to the loss of mitochondrial membrane potential.
Cytochrome c is then released from dysfunctional mitochondria
and accumulates in the cytosol to form a complex with Apaf-1.
Caspase 3 is known to be cleaved in the intrinsic apoptotic pathway31.
Our study showed that caspase 3 was activated by kirenol in a dose-
dependent manner. The caspase 3 inhibitor Ac-DEVD-CHO
reduced apoptosis in antigen-specific T cells induced by kirenol,
indicating that the mitochondrial pathway plays an important role
in the apoptosis of autoreactive T cells induced by kirenol.
In conclusion, the present study demonstrated the therapeutic
potential of kirenol in MS and other autoimmune CNS diseases.
Kirenol reduced the severity of EAE by inhibiting differentiation of
Th1/Th17 cells and inducing apoptosis of MOG-specific T cells
Figure 5 | Kirenol induces T cell apoptosis in vitro. Lymphocytes of DLNs were obtained from EAE mice at day 25. Lymphocytes were stimulated with
MOG35–55 together with increasing concentrations of kirenol for 12 h, 24 h and 36 h, and then cell proliferation was measured by [
3H]-thymidine
incorporation assay. (B) Representative images of CD41AV1 flow cytometry in DLNs that were stimulated with MOG35–55 together with increasing
concentrations of kirenol for 24 h and 36 h are shown. (C) Quantification of the number of CD41AV1 cells.
www.nature.com/scientificreports
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Figure 6 | A mitochondria-dependent pathway is involved in the apoptosis induced by kirenol. Lymphocytes from DLNs in EAE mice at day 25 were
stimulated withMOG35–55 together with different concentrations of kirenol for 36 h and then gated on the CD41 T cells. Next, the expression of caspase
3, Bax, Bcl-2 (A) and cytochrome c (E) in CD41 T cells were analyzed by western blot. Gels have been run under the same experimental conditions.
(B) Lymphocytes were pretreated with or without either the pan-caspase inhibitor z-VAD-fmk (10 mM) or amore specific caspase 3 inhibitor Ac-DEVD-
CHO (10 mM) for 4 h followed by treatment with kirenol (20 mM) for 36 h and the gated on CD41 T cells, and the relative activity of caspase 3 was
measured using a caspase 3 activity assay. The representative images of CD41AV1 flow cytometry (C) and quantification of the number of CD41AV1
cells (D) are shown.
www.nature.com/scientificreports
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through amitochondria-dependent pathway. This novel mechanism
of action may account for the therapeutic potential of kirenol in MS
by elimination of cells responsible for CNS inflammation.
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